A brief history of antidepressant drug development: from tricyclics to beyond ketamine

@article{Pereira2018ABH,
  title={A brief history of antidepressant drug development: from tricyclics to beyond ketamine},
  author={V. Pereira and Vin{\'i}cius A. Hiroaki-Sato},
  journal={Acta Neuropsychiatrica},
  year={2018},
  volume={30},
  pages={307 - 322}
}
Objective Although monoaminergic-targeted drugs have prompted great advances in the development of treatments for depression, the need for new options persists, since these drugs still have a delayed clinical effect and most patients do not respond properly to them. Recently, the observation of the antidepressant effects of ketamine brought on a new wave of studies regarding the comprehension of the neurobiology of depression and the development of new and more effective antidepressant drugs… Expand
Ketamine: a new chapter in antidepressant development
TLDR
Because ketamine’s antidepressant effects are so rapid, and because the onset and offset of its therapeutic effects are fairly predictable, investigators began using ketamine as a tool – both clinically and preclinically – to decipher its mechanistic effects and identify biomarkers of treatment response. Expand
Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators
TLDR
Evidence is focused on evidence that endogenous glutamatergic neuromodulators may be able to modulate mood and to elicit fast antidepressant responses and the possibility that these neurmodulators and ketamine have common neurobiological mechanisms. Expand
Antioxidant Potential of Psychotropic Drugs: From Clinical Evidence to In Vitro and In Vivo Assessment and toward a New Challenge for in Silico Molecular Design
TLDR
A rigorous and systematic analysis of the structural and reactivity properties of antioxidant drugs seems to be a promising route to better interpret therapeutic outcomes and provide elements for the rational design of novel drugs. Expand
Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression
TLDR
A comparative study of FSL and SD rat with respect to behavioral characteristic, neuropeptide levels in various brain regions, and response to long‐term antidepressant treatment revealed that female FSL rats showed the most pronounced depressive‐like phenotype andresponse to SSRI treatment, but these findings were not paralleled by changes in measures of NPY, CRH and CGRP function. Expand
Benefits of animal models to understand the pathophysiology of depressive disorders
  • B. Czéh, M. Simon
  • Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2021
TLDR
It is argued, that despite their evident imperfections, these models provide invaluable help to understand cellular and molecular mechanisms contributing to the development of MDD. Expand
Neuroinflammation and depression: A review
TLDR
The intricated dynamic crosstalk between neuro inflammation and other relevant neurobiological correlates of depression add to evidence that neuroinflammation may be a key therapeutic target for future therapeutic strategies in major depressive disorder. Expand
Prospects for repurposing CNS drugs for cancer treatment
TLDR
It is concluded that Some Central Nervous system drugs show a great potential as anti-cancer in vitro, in vivo and clinical trials through different mechanisms and pathways in different types of cancer that reveal a promising evidence for the repurposing of CNS drugs for new indications. Expand
The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway
TLDR
Repeated ARN-3236 administration induced significant antidepressant-like effects in both the CSDS and CUMS models of depression, accompanied with fully preventing the stress-enhanced SIK2 expression and cytoplasmic translocation of cyclic adenosine monophosphate response element binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) in the hippocampus. Expand
Hippocampal PPARα Plays a Role in the Pharmacological Mechanism of Vortioxetine, a Multimodal-Acting Antidepressant
TLDR
It was found that vortioxetine administration significantly reversed the inhibitory actions of both CUMS and CSDS on the hippocampal PPARα expression, and genetic knockdown of PPAR α in the hippocampus significantly blocked the protecting effects of vortoxetine against bothCUMS andCSDS. Expand
Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies
TLDR
This review focuses on the binding of cognate substrate and drugs belonging to the different families of antidepressants, including tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptakes inhibitors, and multimodal drugs, as well as illicit drugs such as cocaine, amphetamines, and ibogaine. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 177 REFERENCES
Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.
TLDR
The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuroscientific disciplines. Expand
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
TLDR
Preclinical studies are examining compounds with more specific pharmacological effects at glutamate receptors and synapses in order to develop additional rapidly acting antidepressants without the hallucinogenic side effects or abuse potential of ketamine. Expand
Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
TLDR
Questions are raised regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action, and paths to move the field forward are discussed. Expand
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
TLDR
The efficacy, safety, and tolerability of ketamine are discussed, the neurobiology of depression is summarized, the mechanisms underlying the rapid antidepressant effects of ketamines are reviewed, and the prospects for next-generation rapid-acting antidepressants are discussed. Expand
Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics.
TLDR
The onset of drug treatment with convincing antidepressive efficacy is reviewed, and the development and clinical introduction of tricyclics and tetracyclics are recaped. Expand
Pharmacotherapy of depression: a historical analysis
  • T. Ban
  • Psychology, Medicine
  • Journal of Neural Transmission
  • 2001
TLDR
Although one can no longer expect that 2 of 3 depressed patients will respond to treatment, the newer antidepressants are better tolerated, because they produce less anticholinergic side effects. Expand
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
TLDR
A review of stress‐related neurobiology of depression and the safety, tolerability, and efficacy of ketamine for MDD, along with a review ofketamine's mechanism of action and prospective predictors of treatment response are discussed. Expand
New paradigms for treatment‐resistant depression
TLDR
Treatment with NMDA receptor antagonists and magnesium have shown the ability to sprout new synaptic connections and reverse stress‐induced neural changes, opening up promising new territory for the development of drugs to meet the unmet need in patients with clinical depression. Expand
Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy
TLDR
A small body of work to suggest ketamine might also augment electroconvulsive therapy and potentially have a role as a surgical anaesthetic in depressed patients, but there are significant practical and ethical issues about any future mainstream clinical role it might have. Expand
New targets for rapid antidepressant action
TLDR
Clinical evidence supporting the use of novel glutamate receptor modulators with direct affinity for cognate receptors is reviewed, including ketamine, memantine, dextromethorphan, AZD6765 and others. Expand
...
1
2
3
4
5
...